Suven Life Sciences Limited (BOM: 530239)
India
· Delayed Price · Currency is INR 119.80
-0.80 (-0.66%)
At close: Nov 14, 2024
Suven Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 84.15 | 116.93 | 135.39 | 118.44 | 134.78 | 144.15 | Upgrade
|
| Other Revenue | - | - | 0.56 | 1.06 | 5.95 | 2.91 | Upgrade
|
| Revenue | 84.15 | 116.93 | 135.95 | 119.51 | 140.73 | 147.05 | Upgrade
|
| Revenue Growth (YoY) | -32.82% | -13.99% | 13.76% | -15.08% | -4.30% | -94.86% | Upgrade
|
| Cost of Revenue | 8.24 | 8.24 | 5.66 | 24.33 | 1.03 | 0.23 | Upgrade
|
| Gross Profit | 75.91 | 108.69 | 130.29 | 95.18 | 139.7 | 146.83 | Upgrade
|
| Selling, General & Admin | 191.88 | 190.24 | 186.21 | 210.21 | 185.36 | 174.91 | Upgrade
|
| Research & Development | 1,416 | 1,144 | 1,154 | 1,064 | 710.27 | 1,032 | Upgrade
|
| Other Operating Expenses | 57.69 | 52.08 | 45.56 | 39.53 | 33.45 | 92.63 | Upgrade
|
| Operating Expenses | 1,727 | 1,452 | 1,451 | 1,357 | 972.55 | 1,341 | Upgrade
|
| Operating Income | -1,651 | -1,343 | -1,320 | -1,262 | -832.85 | -1,195 | Upgrade
|
| Interest Expense | -1.04 | -1.58 | -2.89 | -5.32 | -8.15 | -4.87 | Upgrade
|
| Interest & Investment Income | 164.25 | 164.25 | 64.16 | 11.26 | 69.79 | 132.13 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.7 | -0.7 | -3.28 | -3.71 | -4.14 | -1.94 | Upgrade
|
| Other Non Operating Income (Expenses) | -27.37 | 0 | - | 0 | - | 0.3 | Upgrade
|
| EBT Excluding Unusual Items | -1,516 | -1,181 | -1,262 | -1,260 | -775.35 | -1,069 | Upgrade
|
| Gain (Loss) on Sale of Investments | 45.49 | 45.49 | 17.92 | 3.56 | 0.61 | 5.02 | Upgrade
|
| Asset Writedown | - | - | -0.02 | -0.86 | - | - | Upgrade
|
| Other Unusual Items | 0.11 | 0.11 | 1.85 | 0.13 | - | - | Upgrade
|
| Pretax Income | -1,470 | -1,061 | -1,183 | -1,220 | -774.74 | -1,064 | Upgrade
|
| Income Tax Expense | -10.02 | -10.02 | - | - | -53.23 | -121.83 | Upgrade
|
| Net Income | -1,460 | -1,051 | -1,183 | -1,220 | -721.51 | -942.18 | Upgrade
|
| Net Income to Common | -1,460 | -1,051 | -1,183 | -1,220 | -721.51 | -942.18 | Upgrade
|
| Shares Outstanding (Basic) | 218 | 218 | 178 | 135 | 127 | 127 | Upgrade
|
| Shares Outstanding (Diluted) | 218 | 218 | 178 | 135 | 127 | 127 | Upgrade
|
| Shares Change (YoY) | 1.84% | 22.31% | 32.29% | 5.88% | - | - | Upgrade
|
| EPS (Basic) | -6.68 | -4.82 | -6.63 | -9.05 | -5.67 | -7.40 | Upgrade
|
| EPS (Diluted) | -6.69 | -4.82 | -6.63 | -9.05 | -5.67 | -7.40 | Upgrade
|
| Free Cash Flow | -1,484 | -1,155 | -1,189 | -1,473 | -1,023 | -1,370 | Upgrade
|
| Free Cash Flow Per Share | -6.80 | -5.29 | -6.67 | -10.93 | -8.04 | -10.76 | Upgrade
|
| Dividend Per Share | - | - | - | 1.000 | - | - | Upgrade
|
| Gross Margin | 90.20% | 92.95% | 95.84% | 79.64% | 99.27% | 99.85% | Upgrade
|
| Operating Margin | -1961.59% | -1148.50% | -971.27% | -1056.14% | -591.80% | -812.40% | Upgrade
|
| Profit Margin | -1734.89% | -898.63% | -869.95% | -1020.82% | -512.69% | -640.71% | Upgrade
|
| Free Cash Flow Margin | -1764.02% | -987.51% | -874.42% | -1232.64% | -727.11% | -931.35% | Upgrade
|
| EBITDA | -1,597 | -1,285 | -1,262 | -1,227 | -797.75 | -1,155 | Upgrade
|
| D&A For EBITDA | 53.55 | 57.89 | 58 | 35.41 | 35.09 | 39.62 | Upgrade
|
| EBIT | -1,651 | -1,343 | -1,320 | -1,262 | -832.85 | -1,195 | Upgrade
|
| Revenue as Reported | 268.08 | 328.23 | 219.88 | 134.46 | 212.32 | 284.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.